

Volume 72, Number 21, May 26, 2009, Supplement 4 www.neurology.org



S3 MANAGEMENT OF PD S66 Experimental surgical approaches S3 Diagnosis 566 Cell-based therapies S5 Imaging 568 Gene therapies S7 Genetic testing 570 MANAGEMENT OF NONDOPAMINERGIC AND S8 Preclinical diagnosis of PD 570 Neuropsychiatric problems S8 Preclinical diagnosis of PD 570 Neuropsychiatric problems S9 PHARMACOLOGIC TREATMENT OF PD 570 Neuropsychiatric problems S9 Etiopathogenesis of PD 570 Mannomic dysfunction S9 Pharmacologic agents used in the symptomatic 580 Consitpation 13 Clinical trials of putative neuroprotective agents 570 Autonomic dysfunction 14 Pharmacologic agents used in the symptomatic 580 Consitpation 15 Pharmacologic agents used in the symptomatic 580 Consitpation 16 Levodopa 582 Orthostatic hypotension 27 Dopamine agonists 582 Sexual problems 28 Levodopa <th>S1</th> <th>INTRODUCTION</th> <th>S64</th> <th>Infusion therapies</th>	S1	INTRODUCTION	S64	Infusion therapies
S3 Diagnosis S66 Cell-bosed therapies S5 Imaging S68 Gene therapies S7 Diagnostic challenges S70 MANAGEMENT OF NONDOPAMINERGIC AND S8 Preclinical diagnosis of PD S70 Neuropsychiatric problems S9 PHARMACOLOGIC TREATMENT OF PD S70 Neuropsychiatric problems S9 PLOUNG CELL STATE			S65	Transcranial magnetic stimulation
S3 Diagnosis S66 Cell-based therapies S5 Imaging 568 Gene therapies S7 Cenetic testing S70 MANAGEMENT OF NONDOPAMINERGIC AND NONMOTOR FEATURES OF PD S8 Preclinical diagnosis of PD S70 Neuropsychiatric problems S9 PHARMACOLOGIC TREATMENT OF PD S70 Neuropsychiatric problems S9 PLOUGH CELL STATE OF PD S70 Autonomic dysfunction S9 Etiopathogenesis of PD S76 Behavioral impairment and mond disturbance S13 Clinical trials of putative neuroprotective agents S79 Autonomic dysfunction S18 Pharmacologic agents used in the symptomatic S80 Consitpation S18 Levodopa S81 Urinary problems S27 Dopamine agonists S82 Sexual problems S28 Sexual problems S81 Their more pulation, sweating and sialorrhea S41 MAO-B inhibitors S85 Paint Agysesthesias S42 Other antiparkinsonian drugs S86 Speech and swallowing difficulties <	S3	MANAGEMENT OF PD	S66	Experimental surgical approaches
S7 Genetic testing S7 MANAGEMENT OF NONDOPAMINERGIC AND S8 Preclinical diagnosis of PD NONMOTOR FEATURES OF PD S9 PREClinical diagnosis of PD 570 Neuropsychiatric problems S9 Neuroprotection 574 Hallucinations and delirium S9 Etiopathogenesis of PD 576 Behavioral impairment and mood disturbance S13 Clinical trials of putative neuroprotective agents 579 Autonomic dysfunction S18 Pharmacologic agents used in the symptomatic 580 Consitpation S18 Levadopa 581 Urinary problems S18 Levadopa 582 Sexual problems S27 Dopamine agonists 582 Orthostatic hypotension S36 COMT inhibitors 584 Thermoregulation, sweating and sialorrhea S41 MAO-B inhibitors 585 Pain/dysesthesias S42 Other antiparkinsonian drugs 586 Speech and swellowing difficulties S44 The issue of neuroprotection 587 Falls S44 The issue of what	S3	Diagnosis	S66	
S7 Genetic testing S7 MANAGEMENT OF NONDOPAMINERGIC AND S8 Preclinical diagnosis of PD NONMOTOR FEATURES OF PD S9 PREClinical diagnosis of PD 570 Neuropsychiatric problems S9 Neuroprotection 574 Hallucinations and delirium S9 Etiopathogenesis of PD 576 Behavioral impairment and mood disturbance S13 Clinical trials of putative neuroprotective agents 579 Autonomic dysfunction S18 Pharmacologic agents used in the symptomatic 580 Consitpation S18 Levadopa 581 Urinary problems S18 Levadopa 582 Sexual problems S27 Dopamine agonists 582 Orthostatic hypotension S36 COMT inhibitors 584 Thermoregulation, sweating and sialorrhea S41 MAO-B inhibitors 585 Pain/dysesthesias S42 Other antiparkinsonian drugs 586 Speech and swellowing difficulties S44 The issue of neuroprotection 587 Falls S44 The issue of what	S5	- Imaging	S68	Gene therapies
S8 Preclinical diagnosis of PD NOMMOTOR FEATURES OF PD S9 PHARMACOLOGIC TREATMENT OF PD \$70 Neuropsychiatric problems S9 Neuroprotection \$74 Hallucinations and delirium S9 Etiopathogenesis of PD \$76 Behavioral impairment and mood disturbance S13 Clinical trials of putative neuroprotective agents \$79 Autonomic dysfunction S18 Pharmacologic agents used in the symptomatic \$80 Consitpation treatment of PD \$81 Urinary problems \$18 Levodopa \$82 Sexual problems \$27 Dopamine agonists \$82 Orthostatic hypotension \$36 COMT inhibitors \$84 Thermoregulation, sweating and sialorrhea \$41 MAO-B inhibitors \$85 Pein/dysesthesias \$42 Other antiparkinsonian drugs \$86 Speech and swallowing difficulties \$44 Pharmacologic approach to patients with early PD \$86 Seborrhea/blepharitis \$45 The issue of what symptomatic agent should be used to initiate therapy \$87 Falls <t< td=""><td>S7</td><td>Genetic testing</td><td></td><td></td></t<>	S7	Genetic testing		
S8 Preclinical diagnosis of PD NOMMOTOR FEATURES OF PD S9 PHARMACOLOGIC TREATMENT OF PD \$70 Neuropsychiatric problems S9 Neuroprotection \$74 Hallucinations and delirium S9 Etiopathogenesis of PD \$76 Behavioral impairment and mood disturbance S13 Clinical trials of putative neuroprotective agents \$79 Autonomic dysfunction S18 Pharmacologic agents used in the symptomatic \$80 Consitpation treatment of PD \$81 Urinary problems \$18 Levodopa \$82 Sexual problems \$27 Dopamine agonists \$82 Orthostatic hypotension \$36 COMT inhibitors \$84 Thermoregulation, sweating and sialorrhea \$41 MAO-B inhibitors \$85 Pein/dysesthesias \$42 Other antiparkinsonian drugs \$86 Speech and swallowing difficulties \$44 Pharmacologic approach to patients with early PD \$86 Seborrhea/blepharitis \$45 The issue of what symptomatic agent should be used to initiate therapy \$87 Falls <t< td=""><td>S7</td><td>Diagnostic challenges</td><td>S70</td><td>MANAGEMENT OF NONDOPAMINERGIC AND</td></t<>	S7	Diagnostic challenges	S70	MANAGEMENT OF NONDOPAMINERGIC AND
S9 PHARMACOLOGIC TREATMENT OF PD S70 Cognitive impairment and dementia S9 Neuroprotection S74 Hallucinations and delirium S9 Etiopathogenesis of PD S76 Behavioral impairment and mood disturbance S13 Clinical trials of putative neuroprotective agents S79 Autonomic dysfunction S18 Pharmacologic agents used in the symptomatic treatment of PD S81 Urinary problems S18 Levodopa S82 Sexual problems S27 Dopamine aganists S82 Orthostic hypotension S36 COMT inhibitors S85 Pain/dysesthesias S41 MAO-B inhibitors S85 Pain/dysesthesias S42 Other antiparkinsonian drugs S86 Speech and swallowing difficulties S44 Pharmacologic approach to patients with early PD S86 Seborrhea/blepharitis S44 The issue of neuroprotection S87 Falls S45 The issue of what symptomatic therapy S88 Freezing of gait and festination S46 The issue of what symptomatic agent should be used to initiate therapy	S8			NONMOTOR FEATURES OF PD
S9 Neuroprotection S74 Hallucinations and delirium S9 Etiopathogenesis of PD S76 Behavioral impairment and mood disturbance S13 Clinical trials of putative neuroprotective agents S79 Autonomic dysfunction S18 Pharmacologic agents used in the symptomatic treatment of PD S81 Urinary problems S18 Levodopa S82 Sexual problems S27 Dopamine agonists S82 Orthostatic hypotension S36 COMT inhibitors S85 Pain/dysesthesias S41 MAO-B inhibitors S85 Poin/dysesthesias S42 Other antiparkinsonian drugs S86 Speech and swallowing difficulties S44 Pharmacologic approach to patients with early PD S86 Seborrhea/blepharitis S44 The issue of neuroprotection S87 Falls S45 The issue of when to initiate symptomatic therapy S8 Freezing of gait and festination S45 The issue of what symptomatic agent should be used to initiate therapy S88 Freezing of gait and festination S49 Pharmacologic ma			S70	Neuropsychiatric problems
S9Etiopathogenesis of PDS76Behavioral impairment and mood disturbance513Clinical trials of putative neuroprotective agentsS79Autonomic dysfunction518Pharmacologic agents used in the symptomatic treatment of PDS81Consitpation518LevodopaS82Sexual problems527Dopamine agonistsS82Orthostatic hypotension536COMT inhibitorsS84Thermoregulation, sweating and sialorrhea541MAO-B inhibitorsS85Pain/dysesthesias542Other antiparkinsonian drugsS86Speach and swallowing difficulties544Pharmacologic approach to patients with early PDS86Seborrhea/blepharitis544The issue of neuroprotectionS87Falls545The issue of what symptomatic therapyS88Seborrhea/blepharitis546The issue of what symptomatic agent should be used to initiate therapyS88Postural instability549Pharmacologic management of advanced PD patients with motor complicationsS88Symptomatic orthostatic hypotension549Motor fluctuationsS88Symptomatic orthostatic hypotension550Management of dyskinesiasS89Sleep disorders in PD551SURGICAL PROCEDURES AND OTHER INVASIVES91Insommia and sleep fragmentation557Ablative proceduresS92RBD and PD557ThalamotomyS93RLS, PLMS, and akathisia557PallidotomyS94Sleep apnea558Deep-Brain Stimu	S9	PHARMACOLOGIC TREATMENT OF PD	S70	Cognitive impairment and dementia
S13Clinical trials of putative neuroprotective agentsS79Autonomic dysfunctionS18Pharmacologic agents used in the symptomatic treatment of PDS81Urinary problemsS18LevodopaS82Sexual problemsS27Dopamine agonistsS82Orthostatic hypotensionS36COMT inhibitorsS84Thermoregulation, sweating and sialorrheaS41MAO-B inhibitorsS85Pain/dysesthesiasS42Other antiparkinsonian drugsS86Speech and swallowing difficultiesS44Pharmacologic approach to patients with early PDS86Sebornhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Freezing of gait and festinationS49Pharmacologic management of advanced PD patients with motor complicationsS88Other neurologic deficitsS49Motor fluctuationsS88Other neurologic deficitsS49Motor fluctuationsS89Environmental causesS53Management of dyskinesiasS89Environmental causesS55SURGICAL PROCEDURES AND OTHER INVASIVES91Insomnia and sleep fragmentationS57Ablative proceduresS92Nightmares and parasomniasS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS57Subthalamotomy	S9	Neuroprotection	S74	Hallucinations and delirium
S18Pharmacologic agents used in the symptomatic treatment of PDS81Urinary problemsS18LevodopaS82Sexual problemsS27Dopamine agonistsS82Orthostatic hypotensionS36COMT inhibitorsS84Thermoregulation, sweating and sialorrheaS41MAO-B inhibitorsS85Pain/dysesthesiasS42Other antiparkinsonian drugsS86Speech and swallowing difficultiesS44Pharmacologic approach to patients with early PDS86Seborrhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Freezing of gait and festination used to initiate therapyS49Pharmacologic management of advanced PD patients 	S9	Etiopathogenesis of PD	S76	Behavioral impairment and mood disturbance
S18Pharmacologic agents used in the symptomatic treatment of PDS81Urinary problemsS18LevodopaS82Sexual problemsS27Dopamine agonistsS82Orthostatic hypotensionS36COMT inhibitorsS84Thermoregulation, sweating and sialorrheaS41MAO-B inhibitorsS85Pain/dysesthesiasS42Other antiparkinsonian drugsS86Speech and swallowing difficultiesS44Pharmacologic approach to patients with early PDS86Seborrhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Freezing of gait and festination used to initiate therapyS49Pharmacologic management of advanced PD patients with motor complicationsS88Symptomatic orthostatic hypotensionS49Motor fluctuationsS88Other neurologic deficitsS49Motor fluctuationsS89Medical causesS51Management of dyskinesiasS89Environmental causesS52SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PDS92Nightmares and parasomniasS57Ablative proceduresS92RBD and PDS57ThalamotomyS94Sleep dianaS57PallidotomyS94Sleep apneaS58Deep-Brain Stimulation (DBS)seep episodesDBS of the VIME	S13	Clinical trials of putative neuroprotective agents	S79	Autonomic dysfunction
S18LevodopaS82Sexual problemsS27Dopamine agonistsS82Orthostatic hypotensionS36COMT inhibitorsS84Thermoregulation, sweating and sialorrheaS41MAO-B inhibitorsS85Pain/dysesthesiasS42Other antiparkinsonian drugsS86Speech and swallowing difficultiesS44Pharmacologic approach to patients with early PDS86Seborrhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Freezing of gait and festinationS49Pharmacologic management of advanced PD patientsS88Symptomatic orthostatic hypotensionS49Motor fluctuationsS88Other neurologic deficitsS49Motor fluctuationsS89Medical causesS53Management of dyskinesiasS89Environmental causesS54Surgical PROCEDURES AND OTHER INVASIVES91Insomnia and sleep fragmentationAPPROACHES FOR THE TREATMENT OF PDS92Nightmares and parasomniasS57Ablative proceduresS92RBD and PDS57ThalamotomyS94Sleep apneaS57SubthalamotomyS94Excessive daytime sleepiness and unintendedS58Deep-Brain Stimulation (DBS)Sepen appreadS58DBS of the VIMNONPHARMACOLOGIC TREATMENTS FOR PD	S18		S80	Consitpation
S27Dopamine agonistsS82Orthostatic hypotensionS36COMT inhibitorsS84Thermoregulation, sweating and sialorrheaS41MAO-B inhibitorsS85Pain/dysesthesiasS42Other antiparkinsonian drugsS86Speech and swallowing difficultiesS44Pharmacologic approach to patients with early PDS86Seborrhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Freezing of gait and festinationS49Pharmacologic management of advanced PD patients with motor complicationsS88Symptomatic orthostatic hypotensionS49Motor fluctuationsS88Other neurologic deficitsS49Motor fluctuationsS89Medical causesS50Management of dyskinesiasS89Environmental causesS51SURGICAL PROCEDURES AND OTHER INVASIVES91Insomnia and sleep fragmentationAPPROACHES FOR THE TREATMENT OF PDS92Nightmares and parasomniasS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS58Deep-Brain Stimulation (DBS)SepExcessive daytime sleepiness and unintendedS58DBS of the VIMS96NONPHARMACOLOGIC TREATMENTS FOR PD		treatment of PD	S81	Urinary problems
COMT inhibitors S41 MAO-B inhibitors S42 Other antiparkinsonian drugs S44 Pharmacologic approach to patients with early PD S45 Seborrhea/blepharitis S44 The issue of neuroprotection S47 Falls S48 Freezing of gait and festination S48 Levodopa-induced dyskinesia S49 Pharmacologic management of advanced PD patients S49 Motor fluctuations S49 Motor fluctuations S49 Management of dyskinesias S53 Management of dyskinesias S55 SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PD S57 Thalamotomy S57 Pallidotomy S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S58 DBS of the GPi S58 DSS of the GPi S58 DSS of the GPi S58 Other neurologic tinn, sweating and sialorrhea S58 Spanidysesthesias S58 Pain/dysesthesias S58 Pain/dysestriss S	S18	Levodopa	S82	Sexual problems
S41MAO-B inhibitorsS85Pain/dysesthesiasS42Other antiparkinsonian drugsS86Speech and swallowing difficultiesS44Pharmacologic approach to patients with early PDS86Seborrhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Freezing of gait and festinationS49Pharmacologic management of advanced PD patients with motor complicationsS88Symptomatic orthostatic hypotensionS49Motor fluctuationsS88Other neurologic deficitsS49Motor fluctuationsS89Medical causesS53Management of dyskinesiasS89Environmental causesS55SURGICAL PROCEDURES AND OTHER INVASIVES91Insomnia and sleep fragmentationAPPROACHES FOR THE TREATMENT OF PDS92Nightmares and parasomniasS57Ablative proceduresS92RBD and PDS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS58Deep-Brain Stimulation (DBS)Seep episodesS58DBS of the VIMS96NONPHARMACOLOGIC TREATMENTS FOR PD	S27	Dopamine agonists	S82	Orthostatic hypotension
S42Other antiparkinsonian drugsS86Speech and swallowing difficultiesS44Pharmacologic approach to patients with early PDS86Seborrhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Levodopa-induced dyskinesiaS49Pharmacologic management of advanced PD patients with motor complicationsS88Symptomatic orthostatic hypotensionS49Motor fluctuationsS89Medical causesS53Management of dyskinesiasS89Environmental causesS53Management of dyskinesiasS89Sleep disorders in PDS55SURGICAL PROCEDURES AND OTHER INVASIVES91Insomnia and sleep fragmentationAPPROACHES FOR THE TREATMENT OF PDS92Nightmares and parasomniasS57Ablative proceduresS92RBD and PDS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS58Deep-Brain Stimulation (DBS)sleep episodesS58DBS of the VIMS96NONPHARMACOLOGIC TREATMENTS FOR PD	S36	COMT inhibitors	S84	Thermoregulation, sweating and sialorrhea
S44Pharmacologic approach to patients with early PDS86Seborrhea/blepharitisS44The issue of neuroprotectionS87FallsS45The issue of when to initiate symptomatic therapyS87Postural instabilityS46The issue of what symptomatic agent should be used to initiate therapyS88Levodopa-induced dyskinesiaS49Pharmacologic management of advanced PD patients with motor complicationsS88Symptomatic orthostatic hypotensionS49Motor fluctuationsS89Medical causesS53Management of dyskinesiasS89Environmental causesS55SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PDS91Insomnia and sleep fragmentationS57Ablative proceduresS92RBD and PDS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS57SubthalamotomyS94Excessive daytime sleepiness and unintendedS58DEep-Brain Stimulation (DBS)sleep episodesS58DBS of the VIMS96NONPHARMACOLOGIC TREATMENTS FOR PD	S41	MAO-B inhibitors	S85	Pain/dysesthesias
The issue of neuroprotection S87 Falls The issue of when to initiate symptomatic therapy S87 Postural instability Freezing of gait and festination used to initiate therapy S88 Levodopa-induced dyskinesia Levodopa-induced dyskinesia Levodopa-induced dyskinesia S88 Symptomatic orthostatic hypotension With motor complications S88 Other neurologic deficits Motor fluctuations S89 Medical causes S89 Environmental causes S89 Sleep disorders in PD S85 SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PD S91 Insomnia and sleep fragmentation APPROACHES FOR THE TREATMENT OF PD S92 Nightmares and parasomnias S57 Ablative procedures S92 RBD and PD S57 Pallidotomy S93 RLS, PLMS, and akathisia S57 Pallidotomy S94 Sleep apnea S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD	S42	Other antiparkinsonian drugs	S86	Speech and swallowing difficulties
The issue of when to initiate symptomatic therapy The issue of what symptomatic agent should be used to initiate therapy S88 Freezing of gait and festination Levodopa-induced dyskinesia Levodopa-induced dyskinesia Levodopa-induced dyskinesia S89 Symptomatic orthostatic hypotension With motor complications S80 Other neurologic deficits Management of dyskinesias S81 Management of dyskinesias S82 Sep disorders in PD S83 Surgical procedures and other invasive APPROACHES FOR THE TREATMENT OF PD S84 Ablative procedures S85 Pallidotomy S87 Pallidotomy S88 Sleep apnea S89 Sleep apnea S89 Sleep apnea S80 Sleep apnea S80 Sleep apnea S81 RLS, PLMS, and akathisia S82 Sleep apnea S83 Sleep apnea S84 Sleep apnea S85 Subthalamotomy S85 Subthalamotomy S86 Deep-Brain Stimulation (DBS) S87 DBS of the VIM S88 NONPHARMACOLOGIC TREATMENTS FOR PD	S44	Pharmacologic approach to patients with early PD	S86	Seborrhea/blepharitis
The issue of what symptomatic agent should be used to initiate therapy \$88 Levodopa-induced dyskinesia S49 Pharmacologic management of advanced PD patients with motor complications \$88 Other neurologic deficits S49 Motor fluctuations \$89 Medical causes S53 Management of dyskinesias \$89 Environmental causes S55 SURGICAL PROCEDURES AND OTHER INVASIVE \$91 Insomnia and sleep fragmentation APPROACHES FOR THE TREATMENT OF PD \$92 Nightmares and parasomnias S57 Ablative procedures \$99 RLS, PLMS, and akathisia S57 Pallidotomy \$94 Sleep apnea S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi \$96 NONPHARMACOLOGIC TREATMENTS FOR PD	S44	The issue of neuroprotection	S87	Falls
S49Pharmacologic management of advanced PD patients with motor complicationsS88Levodopa-induced dyskinesiaS49Motor fluctuationsS88Other neurologic deficitsS53Management of dyskinesiasS89Medical causesS55SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PDS91Insomnia and sleep fragmentationS57Ablative proceduresS92RBD and PDS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS57SubthalamotomyS94Excessive daytime sleepiness and unintendedS58Deep-Brain Stimulation (DBS)sleep episodesS58DBS of the VIMS96NONPHARMACOLOGIC TREATMENTS FOR PD	S45	The issue of when to initiate symptomatic therapy	S87	Postural instability
S49Pharmacologic management of advanced PD patients with motor complicationsS88Symptomatic orthostatic hypotension Other neurologic deficitsS49Motor fluctuationsS89Medical causesS53Management of dyskinesiasS89Environmental causesS55SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PDS91Insomnia and sleep fragmentationS57Ablative proceduresS92RBD and PDS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS57SubthalamotomyS94Excessive daytime sleepiness and unintendedS58Deep-Brain Stimulation (DBS)sleep episodesS58DBS of the VIMS96NONPHARMACOLOGIC TREATMENTS FOR PD	S46	The issue of what symptomatic agent should be	S88	Freezing of gait and festination
with motor complications S49 Motor fluctuations S53 Management of dyskinesias S89 Environmental causes S89 Sleep disorders in PD S55 SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PD S57 Ablative procedures S57 Ablative procedures S57 Fallidotomy S57 Pallidotomy S57 Subthalamotomy S57 Subthalamotomy S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S69 NONPHARMACOLOGIC TREATMENTS FOR PD		used to initiate therapy	S88	Levodopa-induced dyskinesia
S49Motor fluctuationsS89Medical causesS53Management of dyskinesiasS89Environmental causesS89Sleep disorders in PDS55SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PDS91Insomnia and sleep fragmentationS57Ablative proceduresS92Nightmares and parasomniasS57ThalamotomyS93RLS, PLMS, and akathisiaS57PallidotomyS94Sleep apneaS57SubthalamotomyS94Excessive daytime sleepiness and unintendedS58Deep-Brain Stimulation (DBS)sleep episodesS58DBS of the VIMS96NONPHARMACOLOGIC TREATMENTS FOR PD	S49	Pharmacologic management of advanced PD patients	S88	Symptomatic orthostatic hypotension
S53 Management of dyskinesias S89 Environmental causes S89 Sleep disorders in PD S55 SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PD S92 Nightmares and parasomnias S57 Ablative procedures S92 RBD and PD S55 Thalamotomy S93 RLS, PLMS, and akathisia S57 Pallidotomy S94 Sleep apnea S57 Subthalamotomy S94 Excessive daytime sleepiness and unintended S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD		with motor complications	S88	Other neurologic deficits
S55 SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PD S92 Nightmares and parasomnias S57 Ablative procedures S57 Thalamotomy S58 Pallidotomy S59 Sleep apnea S57 Subthalamotomy S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S98 Sleep disorders in PD Insomnia and sleep fragmentation S92 Nightmares and parasomnias S92 RBD and PD S93 RLS, PLMS, and akathisia S94 Sleep apnea S95 Excessive daytime sleepiness and unintended S18 Sleep episodes S18 NONPHARMACOLOGIC TREATMENTS FOR PD	S49	Motor fluctuations	S89	Medical causes
S55 SURGICAL PROCEDURES AND OTHER INVASIVE APPROACHES FOR THE TREATMENT OF PD S92 Nightmares and parasomnias S57 Ablative procedures S57 Thalamotomy S57 Pallidotomy S57 Pallidotomy S57 Subthalamotomy S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S91 Insomnia and sleep fragmentation S92 Nightmares and parasomnias S92 RBD and PD S93 RLS, PLMS, and akathisia S94 Sleep apnea Excessive daytime sleepiness and unintended S18 sleep episodes S18 NONPHARMACOLOGIC TREATMENTS FOR PD	S53	Management of dyskinesias	S89	Environmental causes
APPROACHES FOR THE TREATMENT OF PD S92 Nightmares and parasomnias S57 Ablative procedures S92 RBD and PD S57 Thalamotomy S93 RLS, PLMS, and akathisia S57 Pallidotomy S94 Sleep apnea S57 Subthalamotomy S94 Excessive daytime sleepiness and unintended S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD			S89	Sleep disorders in PD
S57 Ablative procedures S52 RBD and PD S53 RLS, PLMS, and akathisia S54 Pallidotomy S55 Subthalamotomy S57 Subthalamotomy S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S90 RBD and PD RLS, PLMS, and akathisia S94 Sleep apnea Excessive daytime sleepiness and unintended sleep episodes Sleep episodes S96 NONPHARMACOLOGIC TREATMENTS FOR PD	S55	SURGICAL PROCEDURES AND OTHER INVASIVE	S91	Insomnia and sleep fragmentation
S57 Thalamotomy S93 RLS, PLMS, and akathisia S57 Pallidotomy S94 Sleep apnea S57 Subthalamotomy S94 Excessive daytime sleepiness and unintended S58 Deep-Brain Stimulation (DBS) sleep episodes S58 DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD		APPROACHES FOR THE TREATMENT OF PD	S92	Nightmares and parasomnias
S57 Pallidotomy S94 Sleep apnea S57 Subthalamotomy S94 Excessive daytime sleepiness and unintended S58 Deep-Brain Stimulation (DBS) sleep episodes S58 DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD	S57	Ablative procedures	S92	RBD and PD
S57 Subthalamotomy S94 Excessive daytime sleepiness and unintended S58 Deep-Brain Stimulation (DBS) S58 DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD	S57	Thalamotomy	S93	RLS, PLMS, and akathisia
S58 Deep-Brain Stimulation (DBS) sleep episodes S58 DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD	S57	Pallidotomy	S94	Sleep apnea
DBS of the VIM S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD	S57	Subthalamotomy	S94	Excessive daytime sleepiness and unintended
S58 DBS of the GPi S96 NONPHARMACOLOGIC TREATMENTS FOR PD	S58	Deep-Brain Stimulation (DBS)		sleep episodes
, , , , , , , , , , , , , , , , , , ,	S58	DBS of the VIM		
	S58	DBS of the GPi	S96	NONPHARMACOLOGIC TREATMENTS FOR PD
S58 DBS of the STN S97 Education	S58	DBS of the STN	S97	Education
S60 Other issues regarding DBS S97 Support services	S60		S97	Support services
S61 Adverse events associated with DBS S97 Emotional needs assessment	S61		S97	Emotional needs assessment
	S62	What is the best surgical procedure? Who is a	S97	Peer and group support
		candidate for surgery?	S98	Professional counseling
S62 What is the best surgical procedure? Who is a S97 Peer and aroup support				
		. •		•





S98	Legal/financial counseling	S104	Surgical interventions that restore function in
S98	Occupational counseling		patients with advanced PD
S98	Exercise	S105	Interventions that treat nondopaminergic features of
S100	Speech therapy		PD
S100	Nutrition	S106	Neuroprotective treatments
S101	FUTURE DIRECTIONS—WHAT IS IN THE PIPELINE	S106	ACKNOWLEDGMENT
S101	Treatment of early PD		
S102	Treatment of dyskinesias and motor fluctuations	S107	REFERENCES

Publication of this supplement was supported by independent grants from Teva Neuroscience, Boehringer Ingelheim, Novartis/Orion, and Solvay Pharmaceuticals. Editorial assistance was provided by The Curry Rockefeller Group.



72 (21 Supplement 4) *Neurology* 2009;72;S1-S136

This information is current as of May 26, 2009

Updated Information & including high resolution figures, can be found at:

Services http://n.neurology.org/content/72/21_Supplement_4.citation.full

Permissions & Licensing Information about reproducing this article in parts (figures, tables) or in

its entirety can be found online at:

http://www.neurology.org/about/about_the_journal#permissions

Reprints Information about ordering reprints can be found online:

http://n.neurology.org/subscribers/advertise

Neurology ® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

